Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide - PubMed

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

D Teitelbaum et al. Eur J Immunol. 1971 Aug.

Similar articles

• Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

  Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Teitelbaum D, et al. Eur J Immunol. 1973 May;3(5):273-9. doi: 10.1002/eji.1830030505. Eur J Immunol. 1973. PMID: 4128127 No abstract available.

• Protection against experimental allergic encephalomyelitis.

  Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Teitelbaum D, et al. Nature. 1972 Dec 29;240(5383):564-6. doi: 10.1038/240564b0. Nature. 1972. PMID: 4119624 No abstract available.

• Experimental allergic encephalomyelitis: immunological properties of encephalitogenic polypeptides and proteins.

  Lamoureux G, Carnegie PR, McPherson TA, Johnston D. Lamoureux G, et al. Clin Exp Immunol. 1967 Sep;2(5):601-9. Clin Exp Immunol. 1967. PMID: 4965043 Free PMC article.

• The spinal cord protein (SCP): appraisal of physiological and immunological hypotheses of anti-encephalitogenic action.

  MacPherson CF. MacPherson CF. Immunochemistry. 1978 Nov;15(10-11):767-75. doi: 10.1016/0161-5890(78)90107-4. Immunochemistry. 1978. PMID: 85602 Review. No abstract available.

• From immunoneurology to immunopsychiatry: neuromodulating activity of anti-brain antibodies.

  Janković BD. Janković BD. Int Rev Neurobiol. 1985;26:249-314. doi: 10.1016/s0074-7742(08)60076-8. Int Rev Neurobiol. 1985. PMID: 3894271 Review. No abstract available.

Cited by

• Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease.

  Steinman L, Patarca R, Haseltine W. Steinman L, et al. J Exp Med. 2023 Feb 6;220(2):e20221322. doi: 10.1084/jem.20221322. Epub 2023 Jan 18. J Exp Med. 2023. PMID: 36652203 Free PMC article.

• Multiple sclerosis and myelin basic protein: insights into protein disorder and disease.

  Martinsen V, Kursula P. Martinsen V, et al. Amino Acids. 2022 Jan;54(1):99-109. doi: 10.1007/s00726-021-03111-7. Epub 2021 Dec 10. Amino Acids. 2022. PMID: 34889995 Free PMC article. Review.

• Assessing cost-effectiveness in the management of multiple sclerosis.

  Phillips CJ, Humphreys I. Phillips CJ, et al. Clinicoecon Outcomes Res. 2009;1:61-78. doi: 10.2147/ceor.s4225. Epub 2009 Nov 18. Clinicoecon Outcomes Res. 2009. PMID: 21935308 Free PMC article.

• Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

  Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Rommer PS, et al. Clin Exp Immunol. 2014 Mar;175(3):397-407. doi: 10.1111/cei.12206. Clin Exp Immunol. 2014. PMID: 24102425 Free PMC article. Review.

• Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

  Aharoni R, Teitelbaum D, Arnon R, Sela M. Aharoni R, et al. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634-9. doi: 10.1073/pnas.96.2.634. Proc Natl Acad Sci U S A. 1999. PMID: 9892685 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database